An efficient vector system to modify cells genetically

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Han, Huamin ^a,b   Liu, Qingjun ^a   He, Wen ^a,b   Ong, Kristy ^c   Liu, Xiaoli ^d   Gao, Bin ^a  

^a INSTITUTE OF MICROBIOLOGY   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d Epigen Biotec Ltd   (China)

Author keywords

[No Author keywords available]

Indexed keywords

STREPTAVIDIN; VIRUS VECTOR; LIGASE;

ARTICLE; BIOTINYLATION; BIRA GENE; CELL ISOLATION; CELL LABELING; CELL SURFACE; CONTROLLED STUDY; DNA MODIFICATION; DOWNSTREAM PROCESSING; ENZYME SUBSTRATE; GENE; GENE THERAPY; GENE VECTOR; GENETIC TRANSFECTION; LENTIVIRINAE; NONHUMAN; PROTEIN EXPRESSION; VIRAL GENE DELIVERY SYSTEM; CELL LINE; FLOW CYTOMETRY; GENETICS; HUMAN; METABOLISM; PHYSIOLOGY; POLYACRYLAMIDE GEL ELECTROPHORESIS; TUMOR CELL LINE;

MAMMALIA;

BIOTINYLATION; CARBON-NITROGEN LIGASES; CELL LINE; CELL LINE, TUMOR; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FLOW CYTOMETRY; GENETIC VECTORS; HUMANS; TRANSFECTION;

EID: 80855139779     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0026380     Document Type: Article

References (47)

1. Gura T, (2002) Therapeutic antibodies: magic bullets hit the target. Nature 417: 584-586.
2. Fehse B, Uhde A, Fehse N, Eckert HG, Clausen J, et al. (1997) Selective immunoaffinity-based enrichment of CD34+ cells transduced with retroviral vectors containing an intracytoplasmatically truncated version of the human low-affinity nerve growth factor receptor (deltaLNGFR) gene. Hum Gene Ther 8: 1815-1824.
3. Yoshikawa T, Nakanishi F, Ogura Y, Oi D, Omasa T, et al. (2001) Flow cytometry: an improved method for the selection of highly productive gene-amplified CHO cells using flow cytometry. Biotechnol Bioeng 74: 435-442.
4. Yeyati PL, Agmon V, Fillat C, Dinur T, Dagan A, et al. (1995) Fluorescence-based selection of retrovirally transduced cells in the absence of a marker gene: direct selection of transduced type B Niemann-Pick disease cells and evidence for bystander correction. Hum Gene Ther 6: 975-983.
5. Fontanellas A, Mazurier F, Belloc F, Taine L, Dumain P, et al. (1999) Fluorescence-based selection of retrovirally transduced cells in congenital erythropoietic porphyria: direct selection based on the expression of the therapeutic gene. J Gene Med 1: 322-330.
6. Podda S, Ward M, Himelstein A, Richardson C, de la Flor-Weiss E, et al. (1992) Transfer and expression of the human multiple drug resistance gene into live mice. Proc Natl Acad Sci U S A 89: 9676-9680.
7. Bagnis C, Imbert AM, Gravis G, Herrera D, Pavon C, et al. (1995) Hematological reconstitution and gene therapy: retroviral transfer of the bacterial beta-galactosidase activity into human hematopoietic CD34+ cell populations and into T lymphocytes derived from the peripheral blood. Leukemia 9 (Suppl 1): S61-63.
8. Ward M, Pioli P, Ayello J, Reiss R, Urzi G, et al. (1996) Retroviral transfer and expression of the human multiple drug resistance (MDR) gene in peripheral blood progenitor cells. Clin Cancer Res 2: 873-876.
9. Beausejour CM, Eliopoulos N, Momparler L, Le NL, Momparler RL, (2001) Selection of drug-resistant transduced cells with cytosine nucleoside analogs using the human cytidine deaminase gene. Cancer Gene Ther 8: 669-676.
10. Sorrentino BP, Brandt SJ, Bodine D, Gottesman M, Pastan I, et al. (1992) Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1. Science 257: 99-103.
11. Wei K, Huber BE, (1996) Cytosine deaminase gene as a positive selection marker. J Biol Chem 271: 3812-3816.
12. Giaretta I, Madeo D, Bonaguro R, Cappellari A, Rodeghiero F, et al. (2000) A comparative evaluation of gene transfer into blood cells using the same retroviral backbone for independent expression of the EGFP and deltaLNGFR marker genes. Haematologica 85: 680-689.
13. Gotoh H, Matsumoto Y, (2007) Cell-surface streptavidin fusion protein for rapid selection of transfected mammalian cells. Gene 389: 146-153.
14. David R, Groebner M, Franz WM, (2005) Magnetic cell sorting purification of differentiated embryonic stem cells stably expressing truncated human CD4 as surface marker. Stem Cells 23: 477-482.
15. Kawahara M, Inoue T, Ren X, Sogo T, Yamada H, et al. (2007) Antigen-mediated growth control of hybridoma cells via a human artificial chromosome. Biochim Biophys Acta 1770: 206-212.
16. Kawahara M, Kimura H, Ueda H, Nagamune T, (2004) Selection of genetically modified cell population using hapten-specific antibody/receptor chimera. Biochem Biophys Res Commun 315: 132-138.
17. Kawahara M, Ueda H, Morita S, Tsumoto K, Kumagai I, et al. (2003) Bypassing antibiotic selection: positive screening of genetically modified cells with an antigen-dependent proliferation switch. Nucleic Acids Res 31: e32.
18. Kawahara M, Ueda H, Tsumoto K, Kumagai I, Mahoney W, et al. (2002) Selection of highly productive mammalian cells based on an inducible growth advantage using an antibody/receptor chimera. J Biosci Bioeng 93: 399-404.
19. Kawahara M, Ueda H, Tsumoto K, Kumagai I, Nagamune T, (2004) AMEGA: antigen-mediated genetically modified cell amplification. J Immunol Methods 284: 187-194.
20. Beckett D, Kovaleva E, Schatz PJ, (1999) A minimal peptide substrate in biotin holoenzyme synthetase-catalyzed biotinylation. Protein Sci 8: 921-929.
21. Schatz PJ, (1993) Use of peptide libraries to map the substrate specificity of a peptide-modifying enzyme: a 13 residue consensus peptide specifies biotinylation in Escherichia coli. Biotechnology (N Y) 11: 1138-1143.
22. Nesbeth D, Williams SL, Chan L, Brain T, Slater NK, et al. (2006) Metabolic biotinylation of lentiviral pseudotypes for scalable paramagnetic microparticle-dependent manipulation. Mol Ther 13: 814-822.
23. Liu Q, Han H, Zhang Z, Gao B, (2008) [Comparison of two transmemembrane proteins as fusion partner for protein expression on the surface of cell]. Sheng Wu Gong Cheng Xue Bao 24: 1888-1894.
24. Wu Y, Liu C, Sun M, Shen H, Guo D, et al. (2010) A specific cytotoxic T-lymphocyte epitope presentation system for antitumor immunity. Int J Cancer 126: 2373-2386.
25. Morgan RA, Dudley ME, Yu YY, Zheng Z, Robbins PF, et al. (2003) High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens. J Immunol 171: 3287-3295.
26. Yang J, Jaramillo A, Shi R, Kwok WW, Mohanakumar T, (2004) In vivo biotinylation of the major histocompatibility complex (MHC) class II/peptide complex by coexpression of BirA enzyme for the generation of MHC class II/tetramers. Hum Immunol 65: 692-699.
27. Barat B, Wu AM, (2007) Metabolic biotinylation of recombinant antibody by biotin ligase retained in the endoplasmic reticulum. Biomol Eng 24: 283-291.
28. Predonzani A, Arnoldi F, Lopez-Requena A, Burrone OR, (2008) In vivo site-specific biotinylation of proteins within the secretory pathway using a single vector system. BMC Biotechnol 8: 41.
29. Parrott MB, Barry MA, (2001) Metabolic biotinylation of secreted and cell surface proteins from mammalian cells. Biochem Biophys Res Commun 281: 993-1000.
30. Viens A, Mechold U, Lehrmann H, Harel-Bellan A, Ogryzko V, (2004) Use of protein biotinylation in vivo for chromatin immunoprecipitation. Anal Biochem 325: 68-76.
31. Mechold U, Gilbert C, Ogryzko V, (2005) Codon optimization of the BirA enzyme gene leads to higher expression and an improved efficiency of biotinylation of target proteins in mammalian cells. J Biotechnol 116: 245-249.
32. Chen I, Howarth M, Lin W, Ting AY, (2005) Site-specific labeling of cell surface proteins with biophysical probes using biotin ligase. Nat Methods 2: 99-104.
33. Tirat A, Freuler F, Stettler T, Mayr LM, Leder L, (2006) Evaluation of two novel tag-based labelling technologies for site-specific modification of proteins. Int J Biol Macromol 39: 66-76.
34. Parrott MB, Barry MA, (2000) Metabolic biotinylation of recombinant proteins in mammalian cells and in mice. Mol Ther 1: 96-104.
35. O'Brien T, McGinley L, McMahon J, Strappe P, Barry F, et al. (2011) Lentiviral vector mediated modification of mesenchymal stem cells & enhanced survival in an in vitro model of ischaemia. Stem Cell Research & Therapy 2.
36. Lu YA, Cao SB, Wu CX, Yang YB, Sniderhan LF, et al. (2011) Lentiviral vector-mediated stable expression of sTNFR-Fc in human macrophage and neuronal cells as a potential therapy for neuroAIDS. Journal of Neuroinflammation 8.
37. Millington M, Arndt A, Boyd M, Applegate T, Shen S, (2009) Towards a clinically relevant lentiviral transduction protocol for primary human CD34 hematopoietic stem/progenitor cells. PLoS ONE 4: e6461.
38. Bonini C, Grez M, Traversari C, Ciceri F, Marktel S, et al. (2003) Safety of retroviral gene marking with a truncated NGF receptor. Nat Med 9: 367-369.
39. Chung HM, Kim S, Kim GJ, Miyosh H, Moon SH, et al. (2007) Efficiency of the elongation factor-1 alpha promoter in mammalian embryonic stem cells using lentiviral gene delivery systems. Stem Cells and Development 16: 537-545.
40. Fisher PB, Gopalkrishnan RV, Christiansen KA, Goldstein NI, DePinho RA, (1999) Use of the human EF-1 alpha promoter for expression can significantly increase success in establishing stable cell lines with consistent expression: a study using the tetracycline-inducible system in human cancer cells. Nucleic Acids Research 27: 4775-4782.
41. Byun HM, Suh DC, Jeong YS, Wee HS, Kim JM, et al. (2005) Plasmid vectors harboring cellular promoters can induce prolonged gene expression in hematopoietic and mesenchymal progenitor cells. Biochemical and Biophysical Research Communications 332: 518-523.
42. Xia X, Zhang Y, Zieth CR, Zhang SC, (2007) Transgenes delivered by lentiviral vector are suppressed in human embryonic stem cells in a promoter-dependent manner. Stem Cells Dev 16: 167-176.
43. Wang B, He J, Liu C, Chang LJ, (2006) An effective cancer vaccine modality: lentiviral modification of dendritic cells expressing multiple cancer-specific antigens. Vaccine 24: 3477-3489.
44. Nakamura M, Iwahashi M, Nakamori M, Ueda K, Ojima T, et al. (2005) Dendritic cells transduced with tumor-associated antigen gene elicit potent therapeutic antitumor immunity: comparison with immunodominant peptide-pulsed DCs. Oncology 68: 163-170.
45. Lundqvist A, Pisa P, (2002) Gene-modified dendritic cells for immunotherapy against cancer. Med Oncol 19: 197-211.
46. Chang LJ, Zaiss AK, (2002) Lentiviral vectors. Preparation and use. Methods Mol Med 69: 303-318.
47. Kim GG, Donnenberg VS, Donnenberg AD, Gooding W, Whiteside TL, (2007) A novel multiparametric flow cytometry-based cytotoxicity assay simultaneously immunophenotypes effector cells: comparisons to a 4 h 51Cr-release assay. J Immunol Methods 325: 51-66.